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Osteosarcoma (OS) is a rare bone neoplasm that aﬀects mainly adolescents. It is associated with poor prognosis in case of
metastases formation. The search for metastasis predicting markers is therefore imperative to optimize treatment strategies for
patients at risk and important for the search of new drugs for the treatment of this devastating disease. Here, we have analyzed
by microarray the diﬀerential gene expression in four human and two mouse OS cell line systems consisting of parental cell lines
with low metastatic potential and derivatives thereof with increased metastatic potential. Using two osteoblastic cell line systems,
the most common OS phenotype, we have identified forty-eight common genes that are diﬀerentially expressed in metastatic cell
lines compared to parental cells. The identified subset of metastasis relevant genes in osteoblastic OS overlapped only minimally
with diﬀerentially expressed genes in the other four preosteoblast or nonosteoblastic cell line systems. The results imply an OS
phenotype specific expression pattern of metastasis regulating proteins and form a basis for further investigation of gene expression
profiles in patients’ samples combined with survival analysis with the aim to optimize treatment strategies to develop new drugs
and to consequently improve the survival of patients with the most common form of osteoblastic OS.
1. Introduction
Osteosarcoma (OS) is a rare but highly malignant neo-
plasm of bone that aﬀects mainly young patients during
the second decade of their lives. The survival of patients
with localized disease has been improved by refinement of
surgical techniques and by the introduction of neoadjuvant
chemotherapy. However, the survival rate of patients that
develop metastases remains to be low. The identification of
proteins that are involved in OS progression and metastasis
is therefore of immediate importance to develop new and
improved treatment strategies.
The analysis of diﬀerentially expressed genes by microar-
ray, comparing metastatic OS cell lines to parental cell
lines with low metastatic potential, should help to identify
common pathways or even a set of proteins that regulate
OS tumor progression and metastasis. To our knowledge,
four human and two mouse OS systems were developed
that fulfill this requirement. Human metastatic LM5 and
M132 cells were derived from parental SAOS and HUO9
cells, respectively, by in vivo selection in mice carried out
by repeated tail vein injection of cells isolated from lung
metastases [1, 2]. Humanmetastatic 143B cells were obtained
by K-ras transformation of HOS [3] cells and human
metastatic M8 cells by in vitro subcloning of parental MG63
cells as described [4]. Mouse metastatic LM8 and K7M2 cells
were also selected in vivo from parental Dunn and K12 cells,
respectively [5, 6]. Comparative microarray analyses were
performed with HUO9/M132 [7], K12/K7M2 [8], and most
recently with SAOS/LM7 andHOS/143B cells [9]. The results
obtained in these studies imply that diﬀerent sets of proteins
are diﬀerentially expressed in each system and that diﬀerent
signaling pathways are involved in OS tumor progression.
These studies identified ezrin as an important player in OS
pathogenesis [8, 10].
OS is a heterogeneous disease. Diverse cell types orig-
inating from mesenchymal stem cells may be aﬀected by
genomic instability during diﬀerent stages of diﬀerentiation
2 Sarcoma
[11, 12]. Histologically, most of the patients present with
tumors with an osteoblastic (60–70%) phenotype, followed
by chondroblastic and fibroblastic OS (both approximately
10%) [13]. Although there is no evidence for a cell type
dependent propensity to form metastases in OS [13],
diﬀerent pathways involved in tumor progression in such
diverse cell types appear likely. SAOS and Dunn cells are
considered osteoblast-like cells or early osteoblasts as they
express high alkaline phosphatase (ALPL) activity, possess
parathyroid hormone (PTH) responsiveness, and produce
mineralized extracellular matrix upon osteogenic induction
in vitro ([5, 14], and this study). HUO9 are also described
to be osteoblastic [2], but the relatively low ALPL activity
observed in this study suggests that they are preosteoblastic.
MG63 and K12 are considered fibroblastic [15, 16], and
HOS have a mixed type of fibroblastic and epithelial-like
morphology.
In this study we analyzed diﬀerentially expressed genes by
microarray analyses in the four human OS cell line systems
SAOS/LM5, HUO9/M132, HOS/143B, and MG63/M8 and
the two mouse cell line systems Dunn/LM8 and K12/K7M2.
Based on the enrichment of diﬀerentially regulated genes in
common gene ontology (GO) terms, we identified 48 (17
up- and 31 downregulated) commonly regulated genes in OS
metastasis in the two osteoblastic systems (SAOS/LM5 and
Dunn/LM8), that were shared only at a limited number in
the other four cell line systems. The possible role of some
of the identified genes in osteoblastic tumor progression is
discussed.
2. Materials and Methods
2.1. Cell Lines and Culture. SAOS (HTB-85), HOS (CRL-
1543), and 143B (CRL-8303) cells were obtained from ATCC
(Rockville, MD, USA). LM5 cells were kindly provided by
E.S. Kleinerman (M.D. Anderson Cancer Center, Houston,
TX, USA), HUO9 and HUO9-M132 (M132) cells by M.
Tani (National Cancer Center Hospital, Tokyo, Japan), Dunn
and LM8 cells by T. Ueda (Osaka University Graduate
School of Medicine, Osaka, Japan), MG63 cells by G.
Sarkar (Mayo Clinic, Rochester, MN, USA), and MG63-
M8 (M8) cells by W. T. Zhu (Tongji Hospital, Huazhong
University of Science and Technology, Wuhan, China). K12
and K7M2 cells were obtained from C. Khanna (National
Cancer Institute, Bethesda, MD, USA), the former with
permission from J. Schmidt (GSF, National Research Center
for Environment and Health, Neuherberg, Germany) who
established the K12 cells [16]. Cells were cultured in DMEM
(4.5 g/L glucose)/F12 (1 : 1) medium supplemented with
10% heat-inactivated FCS in a humidified atmosphere of 5%
CO2. Subconfluent cells were detached with trypsin/EDTA,
centrifuged and cell pellets immediately frozen in liquid
nitrogen, and stored at −80◦C until RNA extraction.
2.2. RNA Extraction, Array Hybridization, and Analysis. Total
RNA was isolated from frozen cell pellets of individual cell
lines with TriReagent (Sigma-Aldrich, St. Louis, MO) as
described [17]. The RNA was quantified by measuring the
absorption at 260 and 280 nm in a UV-spectrophotometer.
The integrity of the RNA was assessed by standard agarose
gel-electrophoresis and using Bioanalyzer 2100. Comple-
mentary RNA preparation and array hybridization were
performed by the Functional Genomics Center (Zurich,
Switzerland) using Aﬀymetrix Human Genome U133 Plus
2.0 (54675 probe sets) and Aﬀymetrix Mouse Genome 430
2.0 (45101 probe sets) arrays. The gene expression signals
ranged from 5–22000 and 6–31000 in the four human and
two mouse systems, respectively. The distribution of gene
expression levels (log2) was similar in the two array types
as exemplified for the SAOS/LM5 and Dunn/LM8 systems
(Supplementary Figure 1 of the Supplementary Material
available at doi:10.1155/2012/937506). Gene expression lev-
els were arbitrarily set as low, intermediate, and high when
values were <50, 50–300, and >300, respectively. By this
criterion approximately 60% of the genes were expressed at
a low level, 20% were expressed at intermediate, and the
remaining 20% at high levels in both types of arrays. Quality
control, RMA normalization of raw data, and statistical
analysis were performed using RACE (http://race.unil.ch/).
Gene ontology (GO) analysis was performed using GOEAST
(http://omicslab.genetics.ac.cn/GOEAST/). We used Ingenu-
ity Pathway Analysis (IPA) version 12710793, build 162830.
In the first step of a so-called core analysis, the genes
(molecules) that belong to the regulated probe sets are
identified. Next, the cutoﬀ fold-change was adjusted to
select around 800 regulated molecules (to minimize noise,
Ingenuity recommends that approximately 800 molecules,
or less, are analyzed). These molecules are eligible for
generating networks, where (in)direct and relationships
between molecules are shown based on literature findings.
The networks are limited to 35 molecules each in order to
keep them to a usable size.
2.3. cDNA Synthesis and Real-Time PCR Analysis. cDNA
was reverse transcribed from 1 μg of total RNA with a
high-capacity RNA-to-cDNA kit (Applied Biosystems, Foster
City, CA) and the protocol provided by the manufacturer.
Three independent RNA extracts from individual cell lines
were reverse transcribed in a final volume of 20 μL. Real-
time PCR was carried out in a StepOnePlus Real-Time
PCR System (Applied Biosystems) in 96-well plates. Intron-
spanning primers were designed with NCBI Primer blast
(http://www.ncbi.nlm.nih.gov/tools/primer-blast/) software
(Supplementary Table 1) for amplification of cDNA
sequences derived from selected genes. Five genes that were
found upregulated and five genes that were found down-
regulated by microarray analysis in LM5 compared SAOS
cells and GAPDH as a reference gene were analyzed. PCR
from individual RT reactions was carried out in triplicates.
cDNA equivalent to 30 ng of RNA and appropriate primers
were added to Power SYBR Green PCR Master Mix (Applied
Biosystems) and the samples preincubated at 50◦C for 2min
and at 95◦C for 10min and then subjected to 40 cycles
of incubation at 95◦C for 15 s and at 60◦C for 1min. The
threshold for Ct values was set to 0.325 and the obtained
values were analyzed with the delta Ct (ΔCt) method. Mean
Ct values calculated from triplicate PCR were normalized
to mean Ct values determined for GAPDH gene transcripts
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as a measure for cDNA input. The presence of nonspecific
amplification products in any of the PCR reactions was
excluded by inspection of the melting curves of final PCR
products. The data presented in Supplementary Figure 2
confirmed the upregulation of four and the downregulation
of five genes as revealed by the microarray analysis.
2.4. Alkaline Phosphatase Activity, cAMP Stimulation, and
Alizarin Red S Staining. Cell extraction and measurements
of alkaline phosphatase (ALPL) activity, cAMP production
stimulated by chicken parathyroid hormone-related peptide,
the induction of extracellular matrix mineralization, and its
visualization by Alizarin Red S staining were performed as
described [14].
3. Results
3.1. Gene Expression Analysis Reveals Heterogeneity among
Diﬀerent Cell Line Systems and Diﬀerential Gene Expression
in Low and High Metastatic Cell Lines. Four human and
two mouse osteosarcoma cell lines with low metastatic
potential were compared to their high-metastatic derivatives
for diﬀerential gene expression by microarray analysis. The
four human systems with low and upregulated metastatic
activity included the SAOS/LM5, HUO9/M132, HOS/143B,
and MG63/M8 cells. The two mouse systems consisted
of the Dunn/LM8 and K12/K7M2 cells. A comparison of
gene expression levels in the four human systems revealed
that each system clustered together, although the expression
levels clearly diﬀered in low versus high metastatic cell lines
(Figure 1(a)). Interestingly, the two cell line systems that
underwent in vivo selection of the cell line with increased
metastatic potential (SAOS/LM5 and HUO9/M132) were
clearly diﬀerent from the cluster of the HOS/143B (Ki-ras
transformation of HOS) system and the MG63/M8 system
obtained by in vitro selection of M8 from MG63. Clustering
of the two mouse systems with distinct gene expression
levels in low and high metastatic cell lines was also observed
(Figure 1(b)). The number of diﬀerently expressed genes
(i.e., up- or downregulated >2-fold with a false discovery rate
(fdr) of <0.01) in low versus high metastatic cell lines was
highest in HOS/143B and K12/K7M2, lower in SAOS/LM5,
HUO9/M132, and Dunn/LM8, and lowest in MG63/M8.
Only 1% of total probe sets were diﬀerentially regulated
in MG63/M8 whereas 2.5–3.6% (SAOS/LM5, HUO9/M132,
and Dunn/LM8) and 6.7–8.3% were diﬀerentially regulated
in the HOS/143B and K12/K7M2 systems, respectively. These
findings are summarized in Table 1. Taken together, the
results indicate remarkable heterogeneity among the diﬀer-
ent OS cell line systems and also variability in the number of
genes potentially involved in malignancy progression in the
diﬀerent cell lines.
3.2. Plasma Membrane and Extracellular Matrix Proteins
Involved in Binding, Cell Migration, Angiogenesis, and Apop-
tosis Are Diﬀerentially Expressed in Tumor Progression. A
gene ontology (GO) analysis of metastasis-regulated (>2-
fold; fdr < 0.01) genes in all six cell systems revealed an
enrichment (fdr < 0.00001) at the most general level 1
Table 1: Number of regulated (>2-fold; fdr < 0.01) probe sets in
human and mouse OS cell line systems.
System Total (%)a Up (%)b Down (%)b
Human
SAOS/LM5 1351 (2.5) 668 (49) 683 (51)
HUO9/M132 1975 (3.6) 1001 (51) 974 (49)
HOS/143B 3652 (6.7) 1690 (46) 1962 (54)
MG63/M8 521 (1.0) 292 (56) 229 (44)
Mouse
Dunn/LM8 1217 (2.7) 494 (41) 723 (59)
K12/K7M2 3749 (8.3) 1769 (47) 1980 (53)
a
Percent of the total number of probe sets represented by the human (54675)
and mouse arrays (45101); bpercent of the total number of regulated probe
sets.
(Table 2). Here, 5 out of 18 “cellular component,” 5 out of 20
“molecular function”, and 18 out of 32 “biological process”
GO terms were significantly enriched, again with a large
variability among the diﬀerent cell systems. For the term
“cellular component,” genes belonging to the terms “cell”
and “extracellular region” were enriched in all cell systems,
followed by “extracellular matrix” (4/6) and “membrane”
(3/6). For the term “molecular function” only genes belong-
ing to the term “binding” were enriched in all cell systems.
The greatest variability was observed in the term “biological
process.” Here, enrichment was observed in all cell systems
in terms of “biological regulation,” “multicellular organismal
process”, “developmental process,” and “biological adhesion,”
followed by “cellular process” (5/6), “response to stimulus”
(4/6), and “signaling” (4/6). In eleven additional terms
enrichment was observed to diﬀerent degrees in the six
cell line systems. Despite the observed heterogeneity, the
results imply that aberrantly expressed binding proteins
in the plasma membrane and the extracellular matrix
that control the regulation of developmental processes and
cellular adhesion are involved in tumor progression in mice
and humans.
A GO analysis at higher and more specific levels, and
with significant nodes between levels and down to the
level 1, revealed an aberrant regulation of diverse biological
processes in the diﬀerent cell systems (Supplementary Table
2). In the SAOS/LM5 cell line system, genes involved in car-
diovascular development and neurogenesis were aberrantly
expressed. In the HUO9/M132 system, heart development
was also aﬀected together with ureteric bud morphogenesis
and genes involved in angiogenesis and cell migration were
highly regulated. In the HOS/143B system, angiogenesis and
cell migration were also deregulated. In addition, apopto-
sis and integrin-mediated cell-cell adhesion were aﬀected.
Genes involved in ERK1 and -2 kinase, MAP kinase, SMAD,
and TGFβ signaling and in ureteric bud, prostate gland,
blood vessel and lung alveolus development, neurogenesis,
and blood coagulation were also significantly enriched in
respective GO terms. In the MG63/M8 system only genes
involved in axon regeneration, cell surface receptor signaling,
and intracellular protein kinase activity were diﬀerentially
regulated. In the Dunn/LM8 system, genes involved in the
4 Sarcoma
M
8
M
G
63
H
O
S
14
3B
SA
O
S
LM
5
M
13
2
H
U
O
9
D
is
ta
n
ce
0.6
0.5
0.4
0.3
0.2
0.1
0
(a)
D
u
n
n
LM
8
K
12
K
7M
2
0.4
0.3
0.2
0.1
0
D
is
ta
n
ce
(b)
Figure 1: (a) Dendrogram of gene expression levels in the four human OS cell line systems. (b) Dendrogram of gene expression levels in the
two mouse OS cell line systems. All probe sets on the arrays were included in the analysis.
regulation of cell migration and apoptosis and extracellular
matrix organization together with epithelium, neuron, blood
vessel, and chondrocyte diﬀerentiation were enriched in
respective GO terms. Migration and angiogenesis were
aﬀected in the K12/K7M2 system together with altered
ovarian follicle, mammary gland duct and salivary gland
morphogenesis, and axonogenesis. Taken together, although
no common biological processes were revealed in the six
cell line systems, deregulation of cell migration (4/6),
angiogenesis (3/6) and apoptosis (2/6) may contribute to
tumor progression. The aﬀected developmental processes
weremainly neurogenesis (5/6), cardiovascular (4/6), and the
reproductive system development.
In addition to GO, we also analyzed these data through
the use of Ingenuity Pathways Analysis (IPA; Ingenuity
Systems, http://www.ingenuity.com). The analysis confirmed
all cell systems to be associated with cancerous processes
(ranked as nr. 1 bio function “diseases and disorders” for
all cell systems) (Supplementary Table 3). Also pathways
involved in cellular movement (ranked nr. 1 in all cell
systems, except for LM5) and cardiovascular development
and function (ranked nr. 1 in 5 out of 6 cell systems, ranked
nr. 3 in LM5), with vasculogenesis/angiogenesis pathways
prominently activated, were found to be enriched. These
results therefore confirm the results obtained in the GO
analysis.
3.3. The SAOS/LM5 and Dunn/LM8 Cell Line Systems Are
Representative for Osteoblastic OS. In humans, approxi-
mately two thirds of OS patients present with an osteoblastic
tumor phenotype. We therefore searched for osteoblastic
marker gene expression in our microarray data (Table 3) (for
review see [18]). The transcription factor SOX9, a marker for
osteoblast progenitor cells but not of mature osteoblasts, was
expressed at low to intermediate levels in all cell lines, except
in 143B, where it was upregulated 20-fold in comparison
to HOS cells. RUNX2 (Runt-related transcription factor 2,
also known as CBAF1), an early osteoblast diﬀerentiation
transcription factor which is also required at lower levels
for proper mature osteoblast function, was expressed at
high levels in the Dunn/LM8, SAOS/LM5, HUO9/M132,
and K12/K7M2 systems and at intermediate levels in the
HOS/143B system. In the MG63/M8 system it was upregu-
lated 4-fold from low to intermediate levels in M8 compared
to MG63. OSX (osterix), a transcription factor that acts
downstream of RUNX2, was expressed at intermediate to
high levels in Dunn/LM8, SAOS/LM5, and HUO9/M132
cells. Low expression was observed in K12/K7M2, HOS/143B
and MG63/M8 cells. COL1A1 (collagen 1), SPP1 (osteopon-
tin, bone sialoprotein 1), and IBSP (bone sialoprotein 2) are
produced by maturing and mature osteoblasts. COL1A1 was
expressed at high levels in all cell lines except in 143B, where
it was downregulated 145-fold compared to HOS. SPP1 was
expressed at high levels in the Dunn/LM8, HUO9/M132, and
K12/K7M2 systems and at low levels in the SAOS/LM5 and
MG63/M8 systems. In HOS/143B it was upregulated 17-fold
from low to intermediate levels in 143B compared to HOS
cells. IBSP was only expressed at high levels in the Dunn/LM8
and SAOS/LM5 systems and was low in all other cell line
systems. ALPL (liver/bone/kidney alkaline phosphatase) and
PTH1R (parathyroid hormone receptor 1) are expressed
by late osteoblast-like cells and mature osteoblasts. ALPL
was expressed at high levels only in the Dunn/LM8 and
SAOS/LM5 systems and was low in all other cell lines, except
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Table 2: Number of regulated (>2-fold; fdr < 0.01) probe sets enriched (fdr < 0.00001) in GO terms level 1.
SAOS/LM5 HU09/M132 HOS/143B MG63/M8 Dunn/LM8 K12/K7M2
Cellular component
Cell 884 1244 2519 362 780 2423
Membrane 486 206 475
Extracellular region 196 266 403 96 218 365
Extracellular matrix 78 143 88 134
Synapse 112
Molecular function
Binding 850 1219 2435 343 805 2391
Molecular transducer activity 189 302
Nucleic acid binding transcription factor activity 138 249
Receptor activity 206
Catalytic activity 1062
Biological process
Cellular process 716 1017 2028 638 1858
Biological regulation 517 793 1537 250 522 1378
Response to stimulus 589 1074 376 1010
Multicellular organismal process 400 562 1055 186 369 846
Developmental process 345 490 931 159 351 768
Signaling 399 139 227 567
Biological adhesion 110 145 260 53 70 193
Growth 43 78 85
Locomotion 107 148
Cellular component organization or biogenesis 642 558
Localization 643
Cell proliferation 133
Rhythmic process 57
Reproduction 83
Immune system process 92
Multiorganism process 129
Metabolic process 1132
Death 168
Table 3: Microarray mRNA expression levels of osteoblastic marker genes.
Results are means of the probe sets listed below and analyzed in triplicates. a >2-fold (P < 0.05) versus parental cell line. White, low expression
(<50): yellow, intermediate expression (50–300); green, high expression (>300). Probe sets (human/mouse): SOX9 (202935 s at/1451538 at) RUNX2
(232231 at/1424704 at); OSX (1552340 at/1418425 at); COL1A1 (1556499 s at/1423669 at); SPP1 (209875 s at/1449254 at); IBSP (236028 at/1417484 at);
ALPL (215783 s at/1423611 at); PTH1R (205911 at/1417092 at).
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in the HOS/143B system where it was upregulated 10-fold
from low to intermediate levels in HOS compared to 143B
cells. PTH1R was expressed at intermediate to high levels
in the Dunn/LM8, SAOS/LM5, and HUO9/M132 cell lines
and at low levels in the K12/K7M2 and MG63/M8 cell
lines. Similar to ALPL, PTH1R was upregulated 3-fold from
low to intermediate levels in HOS compared to 143B. In
summary, only the Dunn/LM8 and SAOS/LM5 cell lines
exhibited gene expression characteristics of osteoblast-like
cells. HUO9/M132 and K12/K7M2 cell lines appear to be
osteoblastic precursors that were stalled in the osteoblastic
diﬀerentiation process at an intermediate step, whereas the
HOS/143B and MG63/M8 lines were stalled at an early stage.
The high ALPL gene expression in Dunn/LM8 and
SAOS/LM5 was confirmed by measuring the enzyme activity
in cell extracts (Figure 2). Althoughminimal enzyme activity
was detectable in HUO9, M132, and HOS cells, it was 25-
fold lower compared to Dunn/LM8 and SAOS/LM5, whereas
no enzyme activity was measurable in the other cell lines.
The osteoblast-like phenotype of SAOS/LM5 cells, including
PTH (parathyroid hormone) stimulated cAMP production
and the formation of mineralized extracellular matrix has
already been described [14]. In the present study, PTH
stimulated cAMP production also in Dunn (129 ± 27-fold;
n = 4, P < 0.02) and LM8 cells (111 ± 17-fold; n = 3,
P < 0.03) and mineralization of extracellular matrix upon
induction with ascorbic acid, beta-glycerophosphate, and
dexamethasone was also observed (not shown). In summary,
the enzyme activity profile of the Dunn/LM8 and SAOS/LM5
cell lines paralleled the expression profile obtained with
gene expression analysis, confirming their osteoblast-like
properties at a functional level.
3.4. The Osteoblastic OS Cell Line Systems Present with
an Enriched Set of Commonly Regulated Genes as Potential
Targets for OS Treatment. In face of a similar number
of regulated metastasis-related genes in Dunn/LM8 and
SAOS/LM5 cell line systems (Table 1) and a similar enrich-
ment pattern in GO terms (Table 2), we investigated if
both systems had commonly regulated genes that might
contribute to tumor progression and metastasis specific
for osteoblastic OS. First, regulated (>2-fold; fdr < 0.01)
probe set lists in both systems were separated in up- and
downregulated probe set lists in metastatic versus parental
cell lines. Second, separated up- and downregulated probe set
lists were analyzed in GO for commonly enriched GO terms
at the levels indicated in Supplementary Table 4. Upregulated
probe sets were enriched in both systems in four GO terms
and downregulated probe sets in seven GO terms. The GO
probe set lists were then analyzed for commonly regulated
genes (average of approximately 1.4 probe sets/gene) in both
cell line systems and the results are summarized in Table 4.
Using this strategy, we found 48 genes to be unidirectionally
regulated in both Dunn/LM8 and SAOS/LM5 cell line
systems, of which 17 genes were upregulated and 31 genes
were downregulated. Real-time PCR analysis confirmed the
upregulation of 4 out of 5 and the downregulation of 5
out of 5 genes that were selected based on the results of
the microarray analysis of the SAOS/LM5 cell line system
(Supplementary Figure 2). This is well within the range we
previously observed by PCR and/or Western blot analysis for
other gene products in this and other cell line systems (not
shown).
From the relative frequencies given in Table 1, we can
calculate the number of genes to be up- or downregulated in
both systems by chance to be between 4 to 6, when analyzing
the total datasets. As we have restricted our analysis to genes
only enriched in some common GO terms in both cell line
systems, the number of commonly regulated genes (48) by
far exceeds the number of genes that would be selected
by chance. Therefore, these genes can be considered to be
relevant in osteoblastic OS metastasis. In the remaining four
cell line systems, we found that of the 17 upregulated genes
in our osteoblastic gene panel 1, 4, 4, and 0 genes were also
upregulated in M132, K7M2, 143B, and M8, respectively, but
similar numbers of genes were found to be regulated in the
opposite direction as well. Likewise, of the 31 genes found
downregulated 3, 5, 9, and 0 genes were also downregulated
in M132, K7M2, 143B, and M8, respectively, but again
similar numbers of genes were regulated in the opposite
direction. Given the fact that in 143B, and K7M2 the total
number of regulated genes was double the number found
in M132, LM5, and LM8 cells, whereas compared to M8
cells the total number was only half (Table 1), it is likely
that these genes may be commonly regulated by chance and
do not necessarily contribute to tumor progression in these
preosteoblast or nonosteoblastic systems.
We next looked in IPA if the 48 genes in our selected
osteoblastic panel belonged to a specific pathway. This
analysis revealed that half of the selected genes (24 out of
48) are related to inhibition of cell death, making it the
top molecular and cellular function. Pathways related to
cellular growth and proliferation were also stimulated, with
the functions “proliferation of cells” and “proliferation of
tumor cell lines” significantly enriched. The function “colony
formation of (tumor) cells” was inhibited. Surprisingly,
we also found the function “migration of cells” to be
inhibited, most notably by inhibition of SERPINE2, although
the expression of PAX3 (included in the same function
and associated with increased migration) was found to be
increased, indicating some variability in this function.
Three networks were found to be significantly regu-
lated, of which “cell morphology, cellular assembly and
organization, cellular function and maintenance” obtained
the highest score with 21 regulated molecules of a total
of 35 (Supplementary Figure 3), followed by “cell death,
cell morphology, cell-to-cell signaling and interaction” (13
regulated out of 35) and “free radical scavenging, small
molecule biochemistry, nervous system development and
function” (12 regulated out of 35). These last two networks
were found to be overlapping.
One interesting feature of IPA is to identify upstream
regulators, such as transcription factors, that may not show
an expressional change (and are therefore not included in the
analyzed gene list), but are nevertheless likely to be activated
based on a change in target gene expression. Using this
approach, RUNX2 was identified as one of the top activated
transcription factors, because its direct targets COL24A1,
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Table 4: Commonly up- and downregulated genes in metastasis.
Gene name Swiss-Prot LM5 LM8 M132 K7M2 143B M8 Expected OS outcome
Up-regulated in LM5 and LM8
SERPINE2 P07093 3.2 3 4.1 −240 2.2 n.s. Regression [25]
FHOD3 Q2V2M9 3.1 2.9 −2.8 18.9 5.5 n.s.
PAX6 P26367 2.2 2.7 1.9 7.5 −19.6 n.s.
EMILIN2 Q9BXX0 2.8 4.1 n.s. 3.1 −2.1 n.s.
ZDHHC21 Q8IVQ6 2.6 2.5 −1.8 n.s. 2.6 n.s.
GALNT3 Q14435 2.4 2.6 n.s. n.s. 5.1 n.s.
DLX4 Q92988 3 3.2 n.s. 3.6 −5.7 n.s.
FOXQ1 Q9C009 3.8 2.3 n.s. n.s. 1.6 n.s.
LOX P28300 5.8 6.5 −2.5 −3.3 −1.9 n.s. Progression [54]
PAX3 P23760 2.3 2.1 n.s. n.s. n.s. n.s. Progression [39, 40]
COL24A1 Q17RW2 24.3 4.2 n.s. n.s. n.s. n.s.
MAMDC2 Q7Z304 14.8 6.3 n.s. n.s. −129 n.s.
PCBD1 P61457 3.1 4.2 n.s. n.s. n.s. n.s.
PCDHB7 Q9Y5E2 7.6 3 n.s. −1.5 n.s. n.s.
PHOSPHO1 Q8TCT1 4 2.2 n.s. n.s. n.s. n.s.
APCDD1 Q8J025 2.6 7.7 n.s. n.s. n.s. n.s.
EHF Q9NZC4 2.6 10.8 n.s. n.s. n.s. n.s.
Down-regulated in LM5 and LM8
CCDC80 Q76M96 −4.4 −2.6 −2.1 −2.2 −3.4 n.s.
DAB2 P98082 −2.7 −2.1 −2.2 2 −15.3 n.s.
TGFB2 P61812 −2.6 −2.4 1.9 −3.3 −10.9 n.s. Progression [72]
SLC1A3 P43003 −2.1 −4 3.1 −5.8 −6.5 n.s. Regression [73]
OSMR Q99650 −6.8 −2.2 n.s. −2.5 −2 n.s. Progression [15, 76, 77]
CTSH P09668 −2.1 −2.8 −1.6 n.s. −2.6 n.s.
AGPAT3 Q9NRZ7 −2.5 −10.7 1.8 −1.9 −1.4 n.s.
ACTA2 P62736 −5.9 −6.8 4.7 1.5 −107 n.s.
TPM1 P09493 −2.7 −2.3 4.5 n.s. −5.4 n.s.
FOXC2 Q99958 −3.1 −2.1 −3.1 n.s. n.s. n.s.
TPD52L1 Q16890 −2.1 −8.7 2.3 39 −40.7 n.s.
PRUNE2 Q8WUY3 −7.9 −8.8 n.s. n.s. −2.1 n.s.
SH3RF3 Q8TEJ3 −2.3 −2.1 2.4 −12.9 2.8 2
DEPDC6 Q8TB45 −3 −2.5 −1.9 8 n.s. n.s.
OGN P20774 −2.4 −2.6 n.s. −1.9 n.s. n.s.
STRBP Q96SI9 −2.1 −2.4 n.s. −1.5 n.s. n.s.
DNAJC12 Q9UKB3 −2.3 −3.4 n.s. −1.3 n.s. n.s.
NACC2 Q96BF6 −2.2 −2.6 n.s. 1.4 −2 n.s.
SLC40A1 Q9NP59 −2.7 −7.3 n.s. n.s. −2 n.s.
SNCA P37840 −2.2 −2.2 n.s. n.s. 3.1 n.s.
IGFBP4 P22692 −2.3 −2.8 2.2 2.5 n.s. n.s.
RAC3 P60763 −2.7 −2.4 n.s. n.s. 1.9 n.s.
AMIGO2 Q86SJ2 −2.9 −2.5 n.s. 2.8 n.s. n.s.
ETV1 P50549 −8.4 −3.5 n.s. 11.4 2.8 n.s.
PLXNA2 O75051 −3.2 −3.4 n.s. 3.5 1.8 2.9
HAPLN1 P10915 −2.8 −10.1 1.5 n.s. n.s. n.s.
PHLDA1 Q8WV24 −2.1 −9 n.s. 2 48.2 n.s. Progression [88, 89]
PPP1R13B Q96KQ4 −2.2 −2.2 1.8 n.s. n.s. n.s.
TBC1D8 O95759 −2.2 −3.6 n.s. n.s. 5.3 n.s.
ABCC4 O15439 −2.8 −6.7 n.s. 1.7 n.s. n.s.
SYNGR1 O43759 −2.9 −2.9 n.s. n.s. n.s. n.s.
Positive numbers are upregulated genes and negative numbers downregulated genes in metastatic versus parental cell lines. For LM5 and LM8: >±2-fold (fdr
< 0.01). For M132, K7M2, 143B, andM8: yellow (>±2-fold (fdr < 0.01) in the same direction as LM5 and LM8; white (fdr < 0.01); red (>±2-fold (fdr < 0.01)
in the opposite direction as LM5 and LM8; n.s., not significant (fdr > 0.01). Gene names and Swiss-Prot (http://www.expasy.org/) numbers refer to human
proteins.
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Figure 2: (a) RMA normalized ALPL (human: 215783 s at; mouse: 1423611 at) mRNA expression. (b) ALPL enzyme activity.
TPM1, HAPLN1, and ACTA2 were present among the
common regulated genes. Likewise, we identified MEIS2
(targets ETV1, PAX3, PAX6) to be significantly active. This
transcription factor has not been associated to OS metastasis
before, but was earlier found to be regulated in lung cancer
[29], ovarian cancer [30], thyroid cancer [31], and prostate
cancer [32].
4. Discussion
Metastasis-related microarray analyses have been performed
using parental low metastatic HUO9, K12; HOS and
SAOS cells and metastatic derivatives thereof [7–9]. Seven
metastasis-related genes were described for the HUO9/M132
system and we found all these genes also diﬀerentially
regulated in the same direction in our array. From the eleven
genes described to be metastasis related in the K12/K7M2
system we found an overlap of 70%. This was also seen for
the ten top upregulated genes in the HOS/143B cell line
system. A 50% overlap was also observed when we compared
our SAOS/LM5 system with the SAOS/LM7 system [9].
Generally, a high overlap in diﬀerentially regulated genes was
observed when diﬀerent microarray analyses were compared.
Several biological processes involved in tumor pro-
gression, such as proliferation, motility, invasion, immune
surveillance, adhesion, and angiogenesis, have been identi-
fied in the K12/K7M2 system [8]. We have also found enrich-
ment in the GO terms “proliferation,” “motility,” “adhesion,”
and “angiogenesis” although at lower levels than those listed
in Supplementary Table 2. This again confirms a high overlap
between the two independent analyses of this system. The
former study identified ezrin as the most prominent protein
involved in OS progression. We therefore looked for ezrin
expression in our six cell line systems. Indeed, ezrin was
overexpressed 70-fold in K7M2 compared to K12 cells.
However, in LM8 and 143B cells, ezrin was downregulated
1.8- and 2.7-fold compared to the respective parental cells
and in the MG63/M8 system it was not regulated. In LM5
and M132 cells it was found only minimally upregulated
(<2 fold) compared to levels in corresponding parental cells.
Thus, based on these in vitro gene expression analyses, ezrin
may only play a role in OS progression in a subgroup of OS
tumors.
The comparison of gene expression levels in six cell line
systems revealed a high heterogeneity, illustrated by the more
than 7-fold diﬀerence in the total number of diﬀerentially
expressed probe sets. The enrichment in common GO terms
was also low. This indicates that the cellular mechanisms
involved in tumor progression diﬀer in each system. This
is in line with the hypothesis that genomic instability
(chromothripsis) arising at diﬀerent steps of osteoblastic
commitment is a cause of OS oncogenesis [12]. In the
SAOS/LM5 and Dunn/LM8 cell line systems, in which we
confirmed the osteoblast-like nature, the still high RUNX2
expression makes it likely that chromothripsis took place
at an early-osteoblast stage [11]. In addition, these two
osteoblast-like cell line systems had the highest overlap in
the number of regulated metastasis relevant genes and in GO
enrichment. An analysis of a subset of diﬀerentially expressed
genes that were enriched in common GO terms revealed
common regulation of 48 genes in the osteoblastic cell line
systems, exceeding the gene number expected from probabil-
ity calculations. Thus, these genes are likely to contribute to
tumor progression or chromothripsis survival in osteoblastic
OS. According to the chromothripsis hypothesis, diﬀerent
sets of proteins are then likely to contribute to survival
in diﬀerent cancer cell types or in osteoprogenitor cells at
diﬀerent developmental stages as observed in this study.
Seventeen genes were commonly upregulated in the two
metastatic osteoblastic cell lines LM5 and LM8 compared to
the corresponding parental cell lines. The relevance of some
of these genes is now discussed with reference to published
literature on cancer in general and on OS in particular.
SERPINE2 (protease nexin 1) is a secreted serine protease
inhibitor that inhibits among others the blood coagulation
factors Xa and XIa, thrombin, tPA and uPA [33]. Here, SER-
PINE2 was upregulated in metastasis in four out of six cell
line systems and remarkably downregulated in one system.
Increased expression of a protease inhibitor would rather
be expected to reduce invasiveness and hence malignant
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progression, which is also indicated by our IPA analysis.
Indeed, overexpression of SERPINE2 in prostate cancer cells
reduces their invasion capacity [34], and in experimental
OS, inhibition of uPAR pathway resulted in decreased
lung metastasis [19]. In pancreatic tumors, on the other
hand, SERPINE2 promotes extracellular matrix production
and local invasion in vivo [35]. SERPINE2 expression is
elevated in colorectal cancer, correlates with tumor grade
and its silencing reduces anchorage-independent growth,
migration, and tumor formation [36, 37]. SERPINE2 expres-
sion is also increased in breast cancer [38]. SERPINE2
promotes lymph node metastasis of testicular cancer [39]
and SERPINE2 expression also correlates with selective lung
metastasis in breast cancer [40] and lymph node metastasis
of oral squamous cell carcinoma [41]. Metastasis of lung
cancer cells towards bone is also associated with increased
SERPINE2 expression [42]. Thus, SERPINE2 has a dual role
in cancer progression and its role in OS progression, proba-
bly uPA/uPAR independent, may be further investigated.
FHOD3 (formin homolog overexpressed in spleen 2) is a
member of a family of proteins involved in actin assembly
and located in the cytoplasm. FHOD3 is predominantly
expressed in heart and regulates sarcomere organization in
striated muscles [43]. Although there is no evidence yet for
a role of FHOD3 in other cancer types, the downregulation
of FHOD1 (Swiss-Prot Q9Y613), another member of the
family, reduces migration and invasion of breast cancer cells
in vitro [44]. Interestingly, in the present study, FHOD3 was
found upregulated in four metastatic cell lines.
PAX3 (paired box protein Pax-3) and PAX6 (paired box
protein Pax-6) are nuclear transcription factors involved in
the development of many tissues and the role of PAX3 in
rhabdomyosarcoma and malignant melanoma is discussed
[45, 46]. PAX3 is also expressed in most Ewing’s sarcoma
samples [47]. PAX3 was exclusively found overexpressed in
the present study in metastatic osteoblastic OS, whereas
PAX6 was overexpressed in four cell line systems. PAX3 over-
expression in SAOS in vitro induces mesenchymal-epithelial
transition (MET) and increases cell motility (IPA analysis
of LM5–LM8 common regulated genes and [21, 22]),
and therefore PAX3 expression analysis during osteoblastic
tumor progression in vivo deserves further examination.
DLX4 (homeobox protein DLX-4) is a nuclear transcrip-
tion factor that is overexpressed in several cancer types [48–
51]. DLX4 suppresses the antiproliferative eﬀect of TGF-β
[52] and has an antiapoptotic function [53]. Upregulation of
DLX4 increases the metastatic potential of breast cancer cells
in vitro and in vivo [49, 54] and of prostate adenocarcinoma
[51], and its expression correlates with advanced disease
stage in ovarian cancer [50]. Here, DLX4 was also found
upregulated in three cell line systems, but it was downreg-
ulated in 143B cells. To this end, downregulation of DLX4
correlates with increased metastatic potential in vitro and in
vivo in lung cancer [55].
FOXQ1 (forkhead box protein Q19) is a nuclear tran-
scription factor involved in mammary epithelial cell diﬀer-
entiation and in epithelial-mesenchymal transition (EMT)
in breast cancer cells [56–58]. Its expression correlates
with cancer cell aggressiveness in vitro and with lung
metastasis in vivo in mice. FOXQ1 is also overexpressed
in colorectal cancer where it increases tumorigenicity by
its angiogenic and antiapoptotic eﬀects [59]. Here, FOXQ1
was also found overexpressed in metastatic osteoblastic OS
cells. Interestingly, factors that control EMT, such as FOXQ1,
and mesenchymal-epithelial transition (MET), such as PAX3
were overexpressed in OS metastasis in vitro.
LOX (lysyl oxidase; EC 1.4.3.13) is a secreted enzyme
that is involved in extracellular matrix (collagen and elastin)
crosslinking and is also produced by mature osteoblasts [60].
Here, LOX expression was high in all cell lines investigated in
vitro except in SAOS/LM5 cells (not shown). Previously we
showed increased LOX expression in MG63 cells compared
to fetal osteoblasts indicating that LOX might be related to
OS formation [20]. Despite the fact that LOX expression
did not correlate here with the osteoblastic phenotype, LOX
expression was upregulated during metastatic progression in
the two osteoblastic cell line systems, but downregulated in
three out of four nonosteoblastic cell line systems. Tumor
suppressor as well as metastasis promoting functions of LOX
have been described in several cancer types [61]. Analyzing
LOX protein expression in OS patients should answer the
question whether LOX expression has a dual role in OS
progression depending on the cellular background.
PCBD1 (pterin carbinolamine dehydratase or dimeriza-
tion cofactor of hepatocyte nuclear factor (HNF) 1-alpha;
EC = 4.2.1.96) is involved in tetrahydrobiopterin recycling,
a cofactor used in the degradation of the amino acid
phenylalanine. It regulates the transcriptional activity (i.e.,
homodimerization) of HNF and is located in the cytoplasm
and inside the nucleus. It is overexpressed in colon cancer
and in melanoma [62, 63] but to our knowledge has so far
not been described in tumor progression. Here PCBD1 was
exclusively overexpressed in osteoblastic metastatic OS cells.
EHF (epithelium-specific Ets transcription factor 3) is
a nuclear transcription factor involved in breast cancer
tumorigenesis [64] and is a marker for poor survival in ovar-
ian carcinoma [65]. Here, EHF was exclusively overexpressed
in the two osteoblastic metastatic cell lines.
Thirty-one genes were commonly downregulated in
metastatic osteoblastic OS cell lines. The relevance of some
of the genes in OS progression is now discussed.
CCDC80 (downregulated by oncogenes protein 1) is
a secreted tumor suppressor protein that facilitates the
apoptotic cascade [66] and mediates growth inhibition in
colon and pancreatic cancer [67]. CCDC80 was the gene
that was commonly regulated in all cell systems investigated
except MG63/M8. Downregulation of this tumor suppressor
gene deserves further investigation in OS.
DAB2 (disabled homolog 2), a protein of clathrin coated
pits, is a negative regulator of the Wnt/β-catenin pathway
and therefore a putative tumor suppressor [68]. DAB2 is
underexpressed in tumors compared to normal tissue and
correlates with the malignant phenotype of lung cancer,
urothelial carcinoma, squamous cell carcinoma, nasopha-
ryngeal carcinoma, and esophageal squamous carcinoma
[69–73]. DAB2 expression is also reduced in breast cancer,
which results in up-regulation of TGFβ2 that promotes
EMT transition [74, 75]. In ovarian cancer low DAB2 levels
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correlate with poor outcome, but very low levels that inhibit
EMT correlate with a better prognosis [76]. Here, DAB2 was
downregulated in four metastatic OS cell lines.
TGFB2 (transforming growth factor beta-2) is a secreted
protein that can act as a tumor suppressor in early stages
of tumorigenesis or as a metastasis promoting factor in
advanced cancers (for review see [77]). In OS, elevated
TGFB3 expression correlates with poor survival [23]. In the
same study with only 25 patients TGFB2 was not predictive,
but low TGFB2 showed a trend towards poor survival. The
here observed downregulation of TGFB2 in 4 metastatic cell
lines should therefore be investigated further.
SLC1A3 (excitatory amino acid transporter 1) was
found downregulated in metastasis in four cell line systems
contained in this study. This is in contrast with findings in
tumors of OS patients, where high expression of SLC1A3 was
associated with a poor prognosis [24].
OSMR (oncostatin-M-specific receptor subunit beta or
interleukin-31 receptor subunit beta) is a receptor for
oncostatin M (OSM; Swiss-Prot P13725), a member of the
interleukin-6 cytokine family. OSM inhibits cell proliferation
via the JAK/STAT pathway in a number of tumor cells (for
review see [78]), including OS [15] and chondrosarcoma
[79]. In OS, OSM sensitizes cells to apoptosis [25], and
its overexpression was found to reduce primary tumor
growth and lung metastasis formation in vivo in mice
[26]. These data, and the loss of OSMR in metastatic cell
lines as observed in this study in four of the six analyzed
cell line systems, point to an important role of OSM and
OSMR in inhibition of OS tumor progression. On the other
hand, OSM enhanced the in vitro metastatic activity in a
subset of canine and human OS cells [80]. To this end,
it is interesting to note that OSM had diﬀerent eﬀects on
osteoblastic diﬀerentiation, depending on the maturation
stage [15].
TPM1 (tropomyosin alpha-1 chain) is an actin filament-
binding protein with diverse biological actions including
malignant transformation (for review see [81]), and it is
considered as a tumor suppressor gene. TPM1 was found
downregulated in colorectal cancer compared to normal
tissue [82]. In breast cancer cells, loss of TPM1 conferred
anoikis resistance [83] and overexpression of TPM1 sup-
pressed anchorage-independent growth [84]. In this study,
TPM1 was found downregulated in three metastatic OS cell
lines.
DEPDC6 (DEP domain-containing mTOR-interacting
protein or DEPTOR) is a negative regulator of mTOR signal-
ing and is therefore expected to be a tumor suppressor [85].
However, high DEPDC6 levels have been correlated with
poor prognosis in myeloma and hepatocellular carcinoma
[86, 87], indicating an oncogenic role. The here observed
downregulation in three metastatic OS cell lines deserves
therefore further examination.
PHLDA1 (pleckstrin homology-like domain family A
member 1 or apoptosis-associated nuclear protein or TSSC3)
is an apoptosis regulator. Downregulation of this protein is
associated withmetastasis progression in breast cancer and in
melanoma [88, 89]. In OS, overexpression of TSSC3 induced
apoptosis in vitro and reduced tumor growth in vivo in mice
[27, 28]. The results are consistent with downregulation of
PHLDA1 in metastatic LM5 and LM8 cells.
Interestingly, some of the discussed proteins are involved
in EMT and MET (PAX3, FOXQ1, and DAB2), TGF/Wnt/β-
catenin signaling (DLX4, DAB2, and TGFB2), JAK/STAT
(OSMR) or mTOR (DEPDC6) pathways. In another micro-
array study, the TGF/Wnt/β-catenin pathway has also been
associated with increased OS metastatic activity [9].
In conclusion, we have identified a significant number
of diﬀerentially expressed genes in low and highly metastatic
osteoblastic OS cell lines. These genes should be considered
for further evaluation as key players in tumor progression in
osteoblastic OS, the predominant phenotype of the disease.
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